Valuation: NetraMark Holdings Inc.

Market Cap 6.59Cr 4.67Cr 4.1Cr 3.82Cr 3.51Cr 447.29Cr 6.69Cr 45Cr 18Cr 221.28Cr 18Cr 17Cr 764.7Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 6.59Cr 4.67Cr 4.1Cr 3.82Cr 3.51Cr 447.29Cr 6.69Cr 45Cr 18Cr 221.28Cr 18Cr 17Cr 764.7Cr EV / Sales 2026 *
164x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
09/07 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
09/07 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
29/06 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
29/06 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
15/05 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
08/05 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
04/05 NetraMark Holdings Inc. Announces Executive Changes CI
22/04 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
20/04 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
09/04 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
25/03 NetraMark Collaborating With Italian Company To Analyze Phase II Oncology Dataset MT
25/03 Netramark Holdings Inc. and Fondazione Per La Medicina Personalizzata Announce Strategic Research Collaboration CI
25/03 NetraMark Brief: Announcing Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset MT
Manager TitleAgeSince
Chief Executive Officer - 17/02/2022
President - 04/07/2022
Director of Finance/CFO 57 18/07/2022
Director TitleAgeSince
Chairman 40 09/06/2025
Director/Board Member - -
Director/Board Member - 16/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-3.77% - - 4.67Cr
+1.09%-2.22%-23.43%+18.94% 2,89000Cr
-6.08%-8.39%-22.21%+664.89% 32TCr
-9.11%-6.70%+149.62%+917.75% 12TCr
+1.80%+4.48%+3.77%+46.75% 9.34TCr
-0.39%-4.68%+67.43%+129.20% 8.97TCr
-1.33%+1.42%-36.19%-14.47% 7.45TCr
+2.89%+1.63%-31.89%+78.27% 6.39TCr
+1.50%+3.62%+10.18%+65.25% 4.53TCr
+2.23%-7.04%-58.34%+30.57% 3.47TCr
Average -0.34%-4.48%+6.55%+215.24% 41.36TCr
Weighted average by Cap. +0.01%-3.51%-15.42%+105.83%

Financials

2026 *2027 *
Net sales 4L 3L 2L 2L 2L 2.72Cr 4L 27.52L 10.77L 1.35Cr 10.67L 10.44L 4.66Cr -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-

Quarterly revenue - Rate of surprise